Other providers build assays.
We build therapies.
We’re developing our own cell therapy to treat Type 1 Diabetes, so our range of analytical and molecular diagnostic tests have been developed to meet international manufacturing and clinical monitoring regulations from the outset. Using predominantly molecular methods we provide the accuracy, quantitation and speed of result that your, and our, advanced therapeutic medical products require.
We innovate for you
We are committed to keeping pace with your innovation and introducing rapid analytical and diagnostic methods into your manufacturing and clinical development that go beyond slow, outdated methods, whilst still meeting the US, EU and British regulatory and pharmacopoeia standards.
When you need to go beyond the norm, we offer you the opportunity to expediently and cost effectively develop validated assays that are specific to your product’s manufacturing and clinical needs.
Rapid Microbial QC
Sterility
Endotoxin
Mycoplasma
Viral/Biosafety
Adventitious viral agents
Replication competent lentivirus / retrovirus (RCL/RCR) detection
Viral vector copy number
Donor viral screening panel (including zoonotic viruses)
Residual contaminants: viral vector, plasmid and host-cell DNA and proteins
Xenotransplantation
DPF herd establishment & monitoring.
PERV screening.
Zoonotic viruses, fungi, parasites
Clinical bioassays
Sample accessioning and cyropreservation
Nucleic acid biomarkers
Genotyping
Cytokine/chemokine profiling
Cell activation/exhaustion markers
Tumour or disease associated biomarkers
Protein and peptide evaluation
Target engagement biomarkers
Cell expansion/persistence analysis
Surrogate markers
